Justin Chakma - 04 Dec 2024 Form 4 Insider Report for ARS Pharmaceuticals, Inc. (SPRY)

Signature
/s/ Kathleen Scott, Attorney-in-Fact
Issuer symbol
SPRY
Transactions as of
04 Dec 2024
Net transactions value
-$1,919,702
Form type
4
Filing time
06 Dec 2024, 19:15:51 UTC
Previous filing
04 Dec 2024
Next filing
12 Dec 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SPRY Common Stock Options Exercise $37,800 +45,000 +33% $0.8400 181,380 04 Dec 2024 Direct
transaction SPRY Common Stock Sale $627,944 -45,000 -25% $13.95 136,380 04 Dec 2024 Direct F1
transaction SPRY Common Stock Options Exercise $41,698 +49,640 +36% $0.8400 186,020 05 Dec 2024 Direct
transaction SPRY Common Stock Sale $701,642 -49,640 -27% $14.13 136,380 05 Dec 2024 Direct F2
transaction SPRY Common Stock Options Exercise $42,000 +50,000 +37% $0.8400 186,380 06 Dec 2024 Direct
transaction SPRY Common Stock Sale $711,615 -50,000 -27% $14.23 136,380 06 Dec 2024 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SPRY Stock Option (Right to Buy) Options Exercise $0 -45,000 -23% $0.000000 149,640 04 Dec 2024 Common Stock 45,000 $0.8400 Direct F4
transaction SPRY Stock Option (Right to Buy) Options Exercise $0 -49,640 -33% $0.000000 100,000 05 Dec 2024 Common Stock 49,640 $0.8400 Direct F4
transaction SPRY Stock Option (Right to Buy) Options Exercise $0 -50,000 -50% $0.000000 50,000 06 Dec 2024 Common Stock 50,000 $0.8400 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The weighted average sale price for the transaction reported was $13.9543, and the range of prices were between $13.77 and $14.28. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F2 The weighted average sale price for the transaction reported was $14.1346, and the range of prices were between $13.95 and $14.35. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F3 The weighted average sale price for the transaction reported was $14.2323, and the range of prices were between $14.00 and $14.48. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F4 Immediately exercisable.